Search Results

You are looking at 21 - 30 of 401 items for :

  • "adjuvant chemotherapy" x
Clear All
Full access

Maxwell T. Vergo and Al B. Benson III

compared with those with stage II (T4b–a,N0), with 5-year survivals of 83% to 91% versus 58% to 79%, respectively, 5 and yet are offered adjuvant chemotherapy. Evidence shows that stage II and III disease have very similar gene expression profiles and

Full access

Jeffrey Allen and Mohammad Jahanzeb

Edited by Kerrin G. Robinson

trials. Non-small Cell Lung Cancer Collaborative Group . BMJ 1995 ; 311 : 899 – 909 . 6. Arriagada R Bergman B Dunant A . Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer . N Engl J Med

Full access

Al B. Benson III, J. Pablo Arnoletti, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Paul F. Engstrom, Peter C. Enzinger, James W. Fleshman Jr., Charles S. Fuchs, Jean L. Grem, James A. Knol, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr., Constantinos T. Sofocleous, Alan P. Venook and Christopher Willett

All patients who have resected polyps should undergo total colonoscopy to rule out other synchronous polyps, and should subsequently undergo appropriate follow-up surveillance endoscopy. 64 Adjuvant chemotherapy is not recommended for patients with

Full access

Samuel W. Beenken and Marshall M. Urist

Merkel cell carcinoma (MCC) or neuroendocrine carcinoma of the skin is uncommon, often aggressive, and has a poor prognosis. Complete surgical excision with histologic documentation of clear resection margins is recommended for the primary cancer. Retrospective analysis of clinical data strongly suggests that adjuvant radiotherapy improves local control of MCC, but no evidence has been published that it prolongs survival. Sentinel lymph node biopsy is a useful method of determining the need for regional lymph node dissection in stage I patients. Chemotherapy regimens similar to those employed for small cell carcinoma of the lung have been recommended for advanced MCC. Patients often show an initial response to therapy, but it is usually short-lived. The three-year overall survival for patients with MCC is 31%. Before an improvement in long-term survival can be realized, early detection, appropriate use of surgery and radiation therapy, and the development of effective systemic chemotherapy are required.

Full access

Donna Trauth and Lori J. Goldstein

in the adjuvant chemotherapy of patients with node-positive primary breast cancer . 10 Schiff P Fant J Horowitz S . Promotion of microtubule assembly in vitro by taxol . Nature 1979 ; 227 : 665 – 667 . 11 Parness J Horoxitz

Full access

resection who have not undergone preoperative chemoradiation, capecitabine plus oxaliplatin was added as a category 2A adjuvant chemotherapy option following chemoradiation therapy with continuous 5-FU/RT or bolus 5-FU + leucovorin/RT or capecitabine

Full access

Agda Karina Eterovic, Ossama M. Maher, Joya Chandra, Ken Chen, Jason Huse and Wafik Zaky

in the right cerebellar hemisphere with hydrocephalus ( Figure 1E ). Complete Figure 1. (A) Posttherapy calcification of adrenalectomy and rare viable neuroblastoma cells showing good therapeutic response to adjuvant chemotherapy (hematoxylin

Full access

John G. Phillips, Theodore S. Hong and David P. Ryan

locoregional and distant failure. Chemoradiation is used to lower the rate of local recurrence, and adjuvant chemotherapy is used to lower the rate of both systemic and local recurrence. The initial principles of adjuvant chemotherapy were established before

Full access

Prajnan Das, Yixing Jiang, Jeffrey H. Lee, Manoop S. Bhutani, William A. Ross, Paul F. Mansfield and Jaffer A. Ajani

). In addition, the role of radiation in this disease is being further evaluated. Adjuvant Chemotherapy Adjuvant chemotherapy has not consistently been shown to improve overall survival in gastric cancer; Table 2 summarizes some of the early

Full access

David M. O’Malley

–IV ovarian cancer is the use of maintenance therapy after first-line primary/adjuvant chemotherapy. For patients who achieve a response after platinum-based first-line chemotherapy (± bevacizumab) for advanced disease, olaparib maintenance is a category 1